Thermo Fisher Scientific (NYSE:TMO – Get Free Report) had its price objective cut by research analysts at Stifel Nicolaus from $700.00 to $600.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ price target would indicate a potential upside of 28.50% from the stock’s previous close.
A number of other equities research analysts have also recently issued reports on TMO. Evercore reissued an “outperform” rating and set a $650.00 target price on shares of Thermo Fisher Scientific in a report on Monday, January 5th. Robert W. Baird reduced their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday. DZ Bank began coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $625.55.
View Our Latest Report on Thermo Fisher Scientific
Thermo Fisher Scientific Trading Down 9.2%
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific will post 24.68 EPS for the current year.
Insider Buying and Selling at Thermo Fisher Scientific
In other news, CEO Marc N. Casper sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president directly owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This trade represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 0.33% of the company’s stock.
Institutional Trading of Thermo Fisher Scientific
Several hedge funds and other institutional investors have recently bought and sold shares of TMO. iA Global Asset Management Inc. raised its stake in shares of Thermo Fisher Scientific by 2.3% during the first quarter. iA Global Asset Management Inc. now owns 234,697 shares of the medical research company’s stock valued at $115,361,000 after acquiring an additional 5,246 shares during the last quarter. First Pacific Financial raised its stake in Thermo Fisher Scientific by 1.9% in the first quarter. First Pacific Financial now owns 1,839 shares of the medical research company’s stock worth $904,000 after buying an additional 35 shares in the last quarter. Premier Path Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 1.7% in the 1st quarter. Premier Path Wealth Partners LLC now owns 4,382 shares of the medical research company’s stock worth $2,154,000 after acquiring an additional 73 shares in the last quarter. Granite Harbor Advisors Inc. lifted its position in Thermo Fisher Scientific by 12.9% during the first quarter. Granite Harbor Advisors Inc. now owns 848 shares of the medical research company’s stock valued at $417,000 after buying an additional 97 shares during the period. Finally, Caliber Wealth Management LLC KS boosted its position in shares of Thermo Fisher Scientific by 16.9% in the 1st quarter. Caliber Wealth Management LLC KS now owns 409 shares of the medical research company’s stock worth $201,000 after purchasing an additional 59 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.
More Thermo Fisher Scientific News
Here are the key news stories impacting Thermo Fisher Scientific this week:
- Positive Sentiment: Analysts say the pullback may be overdone — TD Cowen reiterated a Buy on TMO, noting solid fundamentals and growth catalysts later in the year, even while trimming its price target. Thermo Fisher Scientific: Stock Pullback Seen as Overdone
- Positive Sentiment: Management raised full‑year 2026 guidance (EPS and revenue range), signaling confidence in medium‑term demand despite a soft organic start to the year. Thermo Fisher Raises 2026 Outlook Despite First-Quarter Organic Revenue Growth Miss
- Neutral Sentiment: Q1 headline results beat estimates — revenue up ~6% YoY to $11.01B and adjusted EPS of $5.44 — which supports the company’s premium valuation narrative. Thermo Fisher Scientific Reports First Quarter 2026 Results
- Neutral Sentiment: Company flagged modest inflation risk tied to Middle East tensions and noted uneven demand across analytical instruments and specialty diagnostics versus strength in lab products and biopharma services. Thermo Fisher Flags ‘Modest Inflation’ Risk Amid Middle East Tensions
- Negative Sentiment: Market focus landed on weak underlying organic growth and mixed segment trends despite beats; that narrative drove the largest immediate selling pressure after the print. Why Thermo Fisher (TMO) Stock Is Nosediving
- Negative Sentiment: Peer/sector spillover: competitors such as 10x Genomics sold off after TMO’s mixed tone, amplifying downside in life‑science tooling names. Why 10x Genomics (TXG) Shares Are Trading Lower Today
- Negative Sentiment: Broader market and tech weakness on the day (risk‑off flow) intensified selling pressure on cyclical/health‑tech names, compounding stock declines. Stocks Settle Lower on US-Iran Stalemate
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Recommended Stories
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
